drugset / Trial / NCT05914116
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Timeline
- Start
- 2023-08-17
- Primary completion
- 2027-12
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | BNT324 | Other / unclassified | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Itraconazole | Small molecule | — | Oral |
| Subject | Lopinavir | Other / unclassified | — | Oral |
| Subject | Ritonavir | Other / unclassified | — | Oral |